lanreotide (Autogel formulation)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neuroendocrine Tumour With Carcinoid Symptoms
Conditions
Neuroendocrine Tumour With Carcinoid Symptoms
Trial Timeline
Jun 1, 2008 → Aug 1, 2010
NCT ID
NCT00681187About lanreotide (Autogel formulation)
lanreotide (Autogel formulation) is a approved stage product being developed by Ipsen for Neuroendocrine Tumour With Carcinoid Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00681187. Target conditions include Neuroendocrine Tumour With Carcinoid Symptoms.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02365584 | Phase 2 | Terminated |
| NCT00891371 | Phase 2/3 | Completed |
| NCT00842348 | Phase 3 | Completed |
| NCT00681187 | Approved | Completed |
| NCT00517491 | Phase 2 | Withdrawn |
| NCT00326469 | Phase 2 | Completed |
| NCT00216398 | Approved | Completed |
| NCT00149188 | Approved | Completed |
| NCT00210457 | Phase 3 | Completed |
| NCT00234572 | Phase 2/3 | Completed |
Competing Products
20 competing products in Neuroendocrine Tumour With Carcinoid Symptoms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET + [212Pb]VMT-α-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| [212Pb] VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Olaparib | AstraZeneca | Phase 2 | 52 |
| Avelumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab Injection | Merck | Phase 2 | 52 |
| Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab | Merck | Phase 1 | 33 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Irinotecan + Paclitaxel | Merck | Phase 2 | 52 |
| MK-0646 | Merck | Phase 2 | 52 |